These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice. Vazquez G; Gutierrez G; Rosenblat J; Schaffer A; Swainson J; Karthikeyan G; Ravindran N; Lam RW; Do A; Giacobbe P; Hawken E; Milev R BMJ Open; 2022 Sep; 12(9):e060967. PubMed ID: 36581972 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study. Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965 [TBL] [Abstract][Full Text] [Related]
10. Esketamine for treatment resistant depression: a trick of smoke and mirrors? Gastaldon C; Papola D; Ostuzzi G; Barbui C Epidemiol Psychiatr Sci; 2019 Dec; 29():e79. PubMed ID: 31841104 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety of ketamine and esketamine in treatment of depression. Nikayin S; Murphy E; Krystal JH; Wilkinson ST Expert Opin Drug Saf; 2022 Jun; 21(6):777-787. PubMed ID: 35416105 [TBL] [Abstract][Full Text] [Related]
13. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients. Banov MD; Landrum RE; Moore MB; Szabo ST J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009 [TBL] [Abstract][Full Text] [Related]
14. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression. Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388 [No Abstract] [Full Text] [Related]
15. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113 [No Abstract] [Full Text] [Related]
16. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial. Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; van Asselt ADI; Touw DJ; Aan Het Rot M; Schoevers RA BMC Psychiatry; 2019 Nov; 19(1):375. PubMed ID: 31783823 [TBL] [Abstract][Full Text] [Related]
17. Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Kritzer MD; Pae CU; Masand PS Expert Opin Drug Saf; 2022 Jun; 21(6):725-732. PubMed ID: 35475388 [TBL] [Abstract][Full Text] [Related]
18. Effect of esketamine on perioperative depressive symptoms in major surgery patients (PASSION II): study protocol for a randomised controlled trial. Zhou Y; Ma B; Sun W; Wang J; Fu Y; Wang A; Wang G; Han R BMJ Open; 2022 Apr; 12(4):e056713. PubMed ID: 35473735 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469 [TBL] [Abstract][Full Text] [Related]
20. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials. Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]